Obesity programs: <li /> Phase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual agonist tirzepatide ...
Kailera unveiled the Zepbound-matching phase 2 data for KAI-9531 at the start of this year. As Fierce Biotech noted at the time, Zepbound—also a dual GIP and GLP-1 receptor agonist—showed ...
Recent research has highlighted the importance of glucagon-like peptide-1 (GLP-1) and its analogs in this ... dependent insulinotropic polypeptide (GIP) on beta-cell mass under high-fat diet ...
A randomized phase II clinical trial evaluating the safety and efficacy of initial dose adjustment of zolbetuximab plus chemotherapy in patients with HER2-negative and CLDN18.2-positive unresectable ...
A phase 2 study to assess the safety and efficacy of FLX475 (tivumecirnon) combined with pembrolizumab in patients with advanced or metastatic gastric cancer. This is an ASCO Meeting Abstract from the ...
The company announced it would begin a study to see if its gastric balloon, combined with popular GLP-1 medicines like Novo Nordisk's (NVO) Wegovy and Eli Lilly's (LLY) Mounjaro, could improve ...
with Lilly’s dual GLP-1/GIP targeting drug tirzepatide, which is already approved for diabetes as Mounjaro and heading for an FDA filing in obesity next year after the readout of a second phase ...
What is the moon phase today? Today, Jan. 29, 2025, the moon is 30 days old, in the New Moon phase of its lunar cycle. It is 0% illuminated. Moon phases reveal the passage of time in the night sky.
This suggests that GLP-2 acts on other sites within the intestinal environment to facilitate lipid release, which is crucial for maintaining energy balance[3]. Furthermore, recent studies have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback